Evidence map›Paper›PMID 41893999›Full record

ArticleLung2026

Asthma Reporting with Anti-TNFα Drugs used in Inflammatory Joint Diseases: A Vigibase® Study with Disproportionality Analysis.

Matthias Nocenti, François Montastruc, Yannick Degboe, Laurent Guilleminault

Abstract read
PubMed Publisher
In one paragraph

Article in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Matthias NocentiDepartment of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital, Toulouse, France.
François MontastrucDepartment of Medical and Clinical Pharmacology, Faculty of Medicine, Toulouse University Hospital, Toulouse, France.
Yannick DegboeRheumatology Department, Pierre-Paul Riquet Hospital, University, Paul Sabatier Toulouse III, Toulouse, France.
Laurent GuilleminaultDepartment of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital, Toulouse, France. guilleminault.l@chu-toulouse.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Large studies investigating asthma as a potential adverse event of anti-TNFα drugs are lacking. In our study, asthma was more likely to be reported with anti-TNFα drugs compared to biologics and small molecules in RA but exclusively with adalimumab.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidAsthmaTumor Necrosis Factor-alphaAdalimumabAntibodies, MonoclonalEtanerceptHumansInfliximabAdalimumabAntibodies, MonoclonalAntirheumatic AgentsEtanerceptInfliximabTumor Necrosis Factor-alphaAdverse eventAnti-TNFα drugsAsthmaRheumatic diseases

Identifiers

PMID41893999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.